KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Mar 09, 2026 >>  ABB India 5991.5  [ -1.23% ]  ACC 1451.6  [ -3.31% ]  Ambuja Cements 452.4  [ -3.06% ]  Asian Paints 2217  [ -2.75% ]  Axis Bank 1288.35  [ -2.09% ]  Bajaj Auto 9379.15  [ -4.42% ]  Bank of Baroda 288.15  [ -2.40% ]  Bharti Airtel 1867.15  [ -0.23% ]  Bharat Heavy 255.3  [ -1.39% ]  Bharat Petroleum 331.1  [ -6.12% ]  Britannia Industries 5881.9  [ -1.73% ]  Cipla 1320  [ -0.13% ]  Coal India 437.7  [ -0.61% ]  Colgate Palm 2161.4  [ -1.91% ]  Dabur India 465.05  [ -2.89% ]  DLF 574.7  [ -0.57% ]  Dr. Reddy's Lab. 1283.5  [ -1.56% ]  GAIL (India) 148.9  [ -4.31% ]  Grasim Industries 2671.3  [ -1.67% ]  HCL Technologies 1358.6  [ 0.13% ]  HDFC Bank 839.2  [ -2.09% ]  Hero MotoCorp 5455  [ -0.97% ]  Hindustan Unilever 2194  [ -1.44% ]  Hindalco Industries 945.5  [ -1.37% ]  ICICI Bank 1277.4  [ -2.74% ]  Indian Hotels Co. 611.8  [ -1.91% ]  IndusInd Bank 883  [ -3.68% ]  Infosys 1314.35  [ 0.47% ]  ITC 306.1  [ -1.18% ]  Jindal Steel 1148  [ -2.71% ]  Kotak Mahindra Bank 386.05  [ -3.48% ]  L&T 3840  [ -2.76% ]  Lupin 2300  [ -1.90% ]  Mahi. & Mahi 3187.25  [ -4.39% ]  Maruti Suzuki India 13487.25  [ -4.68% ]  MTNL 25.44  [ -5.95% ]  Nestle India 1236.2  [ -1.29% ]  NIIT 62.45  [ -4.42% ]  NMDC 79.18  [ -0.59% ]  NTPC 376.45  [ -1.05% ]  ONGC 270.05  [ -3.17% ]  Punj. NationlBak 115.2  [ -3.44% ]  Power Grid Corpn. 295.25  [ -1.32% ]  Reliance Industries 1424.45  [ 1.37% ]  SBI 1098.7  [ -3.92% ]  Vedanta 709.3  [ -1.65% ]  Shipping Corpn. 233.6  [ -2.93% ]  Sun Pharmaceutical 1807.6  [ 0.48% ]  Tata Chemicals 697.4  [ -1.39% ]  Tata Consumer Produc 1097.25  [ -1.75% ]  Tata Motors Passenge 331.95  [ -5.35% ]  Tata Steel 191.05  [ -3.75% ]  Tata Power Co. 372.9  [ -0.68% ]  Tata Consult. Serv. 2527.7  [ -1.17% ]  Tech Mahindra 1335.5  [ 0.26% ]  UltraTech Cement 11360  [ -5.23% ]  United Spirits 1353.4  [ -2.46% ]  Wipro 198.6  [ 1.59% ]  Zee Entertainment 79.94  [ -2.30% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

VENMAX DRUGS & PHARMACEUTICALS LTD.

09 March 2026 | 12:00

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE154G01022 BSE Code / NSE Code 531015 / VENMAX Book Value (Rs.) 11.15 Face Value 10.00
Bookclosure 27/09/2025 52Week High 37 EPS 0.00 P/E 0.00
Market Cap. 12.49 Cr. 52Week Low 19 P/BV / Div Yield (%) 2.14 / 0.00 Market Lot 1.00
Security Type Other

NOTES TO ACCOUNTS

You can view the entire text of Notes to accounts of the company for the latest year
Year End :2024-03 

(m) Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognised when the Company has a Present Obligation (legal or constructive)
as a result of a past event, it is probable that an outflow of resources embodying economic
benefits will be required to settle the obligation and a reliable estimate can be made of the
amount of the obligation. Contingent Liability is disclosed in case of a present obligation arising
from past events, when it is not probable that an outflow of resources will be required to settle
the obligation or where no reliable estimate is possible. Contingent Liabilities are not recognised
in Financial Statements but are disclosed in the Notes to Accounts. Contingent Asset is a possible
asset that arises from past events and whose existence will be confirmed only by the occurrence
or non-occurrence of one or more uncertain future events not wholly within the control of the
Entity. Contingent Assets are not recognised in Financial Statements and are disclosed in the
Notes when it is virtually certain that economic benefits will inflow to the Company.

(n) Earnings per share (EPS)

Basic EPS is computed using the weighted average number of equity shares outstanding during
the period. Diluted EPS is computed using the weighted average number of equity and dilutive
equity equivalent shares outstanding during the period except where the results would be anti¬
dilutive.

22. Government Subsidy

Subsidy from the Government is recognized when there is reasonable assurance that the company will
comply with the conditions attached to them.

ADDITIONAL INFORMATION TO THE FINANCIAL STATEMENTS

23. Share Capital

There was no change in the share capital of the Company during the year.

24. Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development
Act, 2006

As at 31st March,2024, the Company has no dues to suppliers registered under Micro, Small and Medium
Enterprises Development Act, 2006 (‘MSMED Act’). The disclosures pursuant to the said MSMED
Act are as follows:

Disclosure of payable to vendors as defined under the “Micro, Small and Medium Enterprise Development
Act, 2006” is based on the information available with the Company regarding the status of registration
of such vendors under the said Act, as per the intimation received from them on requests made by the
Company. There are no overdue principal amounts / interest payable amounts for delayed payments to
such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers during the
year or for any earlier years and accordingly there is no interest paid or outstanding interest in this regard
in respect of payment made during the year or on balance brought forward from previous year.

25. Disclosure under regulation 34 (3) of SEBI (Listing Obligations & Disclosure Requirement)
Regulations, 2015

The Company does not have any subsidiaries.

26. Related Party disclosure as required by Accounting standard (AS) 18 “Related Party Disclosure”

There were no Related Party disclosures during the year

27. Applicability of IND AS 108

The Company operates in a Single Segment. Accordingly, disclosures under Indian accounting Standards
(IND AS) 108 on operating segments are not applicable to the company.

30. Capital commitment and contingent liabilities

a) Capital commitment

There are no capital commitment outstanding as at reporting date March 31, 2024 (as at March
31, 2023: NIL)

b) Contingent Liabilities and Commitments

There are no contingent liabilities.

31. The Disclosures of Employee Benefits:

Since there are no employees during the year, no provision has been created for Gratuity or other
retirement benefits.

32. Taxes and Deferred

Tax During the year, the company has incurred loss and consequently no provision for Income Tax has
been made. Deferred Tax asset is not accounted for against the losses since there are no commercial
operations as on the date of balance sheet.

33. Other Statutory Information:

(i) The Company has not been declared willful defaulter by any bank or financial institution or government
or any government authority.

(ii) The Company has not granted Loans or Advances in the nature of loans to promoters, directors, KMPs
and the related parties.

(iii) The Company does not have any transactions with companies which are struck off.

34. Previous year’s figures have been regrouped/reclassified wherever necessary to correspond with the
current year’s classification/disclosure.

As per Our report of even date For and on behalf of the Board of Directors

For PPKG & Co of Venmax Drugs And Pharmaceuticals

Limited

Chartered Accountants, F.R.No.09655S

Sd/- Sd/- Sd/-

Girdhari Toshniwal N.Krishnaiah P. Meena Kumari

PARTNER Managing Director Director

Membership No: 205140 DIN : 07279009 DIN : 10458622

UDIN: 24205140BKALIS 5124
Place : HYDERABAD

Date : 14.05.2024

Venmax Drugs and Pharmaceuticals Limited
CIN: L24230TG1988PLC009102

Shed No.22, Plot No.84, Phase-I,

IDA cherlapally, Rangareddy, 500051
E-mail:
Venmaxdrugs@gmail.com

Website: www.venmaxdrugs.com